questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Oxygénases
Dioxygenases
AlkB enzymes
AlkB enzymes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Tests génétiques
Tests enzymatiques
Métabolites
Réparation de l'ADN
Cancer
Marqueurs biologiques
Activité enzymatique
Symptômes
5
Déficience enzymatique
Troubles neurologiques
Types d'enzymes
Fonction enzymatique
Gestion des symptômes
Gravité
Prévention
5
Prévention
Agents alkylants
Régime alimentaire
Antioxydants
Tests génétiques
Surveillance
Éducation
Sensibilisation
Traitements
5
Thérapie génique
Médicaments ciblés
Supplémentation
Antioxydants
Médecine personnalisée
Déficience enzymatique
Essais cliniques
Thérapies
Efficacité
Résultats à long terme
Complications
5
Gestion des complications
Permanence
Effets secondaires
Traitements
Facteurs de risque
5
Facteurs de risque
Prédispositions génétiques
Environnement
Produits chimiques
Antécédents familiaux
Cancers
Groupes à risque
Agents chimiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "AlkB enzymes : Questions médicales les plus fréquentes",
"headline": "AlkB enzymes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les AlkB enzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-07",
"dateModified": "2025-05-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "AlkB enzymes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dioxygenases",
"url": "https://questionsmedicales.fr/mesh/D049308",
"about": {
"@type": "MedicalCondition",
"name": "Dioxygenases",
"code": {
"@type": "MedicalCode",
"code": "D049308",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "AlkB Homolog 1, histone H2a dioxygenase",
"alternateName": "AlkB Homolog 1, Histone H2a Dioxygenase",
"url": "https://questionsmedicales.fr/mesh/D000071498",
"about": {
"@type": "MedicalCondition",
"name": "AlkB Homolog 1, histone H2a dioxygenase",
"code": {
"@type": "MedicalCode",
"code": "D000071498",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "AlkB Homolog 2, alpha-ketoglutarate-dependent dioxygenase",
"alternateName": "AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase",
"url": "https://questionsmedicales.fr/mesh/D000071499",
"about": {
"@type": "MedicalCondition",
"name": "AlkB Homolog 2, alpha-ketoglutarate-dependent dioxygenase",
"code": {
"@type": "MedicalCode",
"code": "D000071499",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "AlkB Homolog 3, alpha-ketoglutarate-dependent dioxygenase",
"alternateName": "AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase",
"url": "https://questionsmedicales.fr/mesh/D000071500",
"about": {
"@type": "MedicalCondition",
"name": "AlkB Homolog 3, alpha-ketoglutarate-dependent dioxygenase",
"code": {
"@type": "MedicalCode",
"code": "D000071500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.875"
}
}
},
{
"@type": "MedicalWebPage",
"name": "AlkB Homolog 4, lysine demethylase",
"alternateName": "AlkB Homolog 4, Lysine Demethylase",
"url": "https://questionsmedicales.fr/mesh/D000071501",
"about": {
"@type": "MedicalCondition",
"name": "AlkB Homolog 4, lysine demethylase",
"code": {
"@type": "MedicalCode",
"code": "D000071501",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.937"
}
}
},
{
"@type": "MedicalWebPage",
"name": "AlkB Homolog 5, RNA demethylase",
"alternateName": "AlkB Homolog 5, RNA Demethylase",
"url": "https://questionsmedicales.fr/mesh/D000071502",
"about": {
"@type": "MedicalCondition",
"name": "AlkB Homolog 5, RNA demethylase",
"code": {
"@type": "MedicalCode",
"code": "D000071502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.968"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alpha-ketoglutarate-dependent dioxygenase FTO",
"alternateName": "Alpha-Ketoglutarate-Dependent Dioxygenase FTO",
"url": "https://questionsmedicales.fr/mesh/D000071516",
"about": {
"@type": "MedicalCondition",
"name": "Alpha-ketoglutarate-dependent dioxygenase FTO",
"code": {
"@type": "MedicalCode",
"code": "D000071516",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416.139.992"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "AlkB enzymes",
"alternateName": "AlkB Enzymes",
"code": {
"@type": "MedicalCode",
"code": "D000071496",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Shoshana C Williams",
"url": "https://questionsmedicales.fr/author/Shoshana%20C%20Williams",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA."
}
},
{
"@type": "Person",
"name": "Rachel Narehood Austin",
"url": "https://questionsmedicales.fr/author/Rachel%20Narehood%20Austin",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA. raustin@barnard.edu."
}
},
{
"@type": "Person",
"name": "Deyu Li",
"url": "https://questionsmedicales.fr/author/Deyu%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA."
}
},
{
"@type": "Person",
"name": "Zhijie Xu",
"url": "https://questionsmedicales.fr/author/Zhijie%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China."
}
},
{
"@type": "Person",
"name": "Juliet Lee",
"url": "https://questionsmedicales.fr/author/Juliet%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome.",
"datePublished": "2023-09-28",
"url": "https://questionsmedicales.fr/article/37770589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s42003-023-05203-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Next-Generation Sequencing (NGS) Analysis Illustrates the Phenotypic Variability of Collagen Type IV Nephropathies.",
"datePublished": "2023-03-21",
"url": "https://questionsmedicales.fr/article/36981034",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes14030764"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36301899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0276925"
}
},
{
"@type": "ScholarlyArticle",
"name": "A high-impact FN1 variant correlates with fibronectin-mediated glomerulopathy via decreased binding to collagen type IV.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36774238",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pathol.2022.10.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence.",
"datePublished": "2023-07-04",
"url": "https://questionsmedicales.fr/article/37402896",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00408-023-00632-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénases",
"item": "https://questionsmedicales.fr/mesh/D010105"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dioxygenases",
"item": "https://questionsmedicales.fr/mesh/D049308"
},
{
"@type": "ListItem",
"position": 7,
"name": "AlkB enzymes",
"item": "https://questionsmedicales.fr/mesh/D000071496"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : AlkB enzymes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur AlkB enzymes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur AlkB enzymes",
"description": "Comment diagnostiquer une déficience en enzymes AlkB ?\nQuels tests sont utilisés pour évaluer l'activité des enzymes AlkB ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec les enzymes AlkB ?\nY a-t-il des marqueurs biologiques pour les enzymes AlkB ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur AlkB enzymes",
"description": "Quels sont les symptômes d'une déficience en AlkB ?\nLes symptômes varient-ils selon le type d'AlkB ?\nComment les symptômes évoluent-ils avec l'âge ?\nY a-t-il des symptômes spécifiques liés au cancer ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur AlkB enzymes",
"description": "Peut-on prévenir les déficiences en AlkB ?\nY a-t-il des recommandations diététiques ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation sur les risques est-elle importante ?\nLes vaccinations peuvent-elles jouer un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur AlkB enzymes",
"description": "Quels traitements existent pour les déficiences en AlkB ?\nLa supplémentation en nutriments aide-t-elle ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques en cours ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur AlkB enzymes",
"description": "Quelles complications peuvent survenir avec une déficience en AlkB ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications liées à des traitements ?\nLes complications varient-elles selon l'âge ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur AlkB enzymes",
"description": "Quels sont les principaux facteurs de risque pour les déficiences en AlkB ?\nL'environnement joue-t-il un rôle ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nY a-t-il des groupes à risque particulier ?",
"url": "https://questionsmedicales.fr/mesh/D000071496?mesh_terms=Collagen+Type+IV#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en enzymes AlkB ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des enzymes AlkB ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques et des analyses de métabolites peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, mais elles peuvent être utiles pour évaluer des tissus spécifiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les enzymes AlkB ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la réparation de l'ADN, pouvant mener à des cancers ou des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour les enzymes AlkB ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains marqueurs peuvent indiquer l'activité ou la déficience des enzymes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en AlkB ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des anomalies de croissance, des troubles neurologiques et un risque accru de cancer."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'AlkB ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types d'AlkB peuvent entraîner des symptômes variés selon leur fonction."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec l'âge, surtout en cas d'exposition à des agents alkylants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés au cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue, la perte de poids et des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents selon la gravité."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en AlkB ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter les agents alkylants peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à protéger l'ADN contre les dommages."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "L'éducation sur les risques est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser aux risques liés aux agents alkylants est crucial pour la prévention."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles jouer un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les déficiences en AlkB."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences en AlkB ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie génique et des médicaments ciblés pour améliorer la réparation de l'ADN."
}
},
{
"@type": "Question",
"name": "La supplémentation en nutriments aide-t-elle ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que des antioxydants peuvent aider à réduire les dommages à l'ADN."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du type de déficience et des symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent de nouvelles thérapies pour les déficiences en AlkB."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais certains traitements montrent des résultats prometteurs sur le long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en AlkB ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent un risque accru de cancers et des troubles neurologiques graves."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées à des traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent entraîner des effets secondaires et des complications."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon l'âge ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent être plus graves chez les personnes âgées ou immunodéprimées."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des tests de dépistage peuvent aider à surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les déficiences en AlkB ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et l'exposition à des agents alkylants."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques et à des radiations peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers ou de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque particulier ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes exposées à des agents chimiques au travail sont à risque accru."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 02/05/2025
Contenu vérifié selon les dernières recommandations médicales
└─
AlkB Homolog 1, histone H2a dioxygenase
AlkB Homolog 1, Histone H2a Dioxygenase
D000071498
-
D08.811.682.690.416.139.500
└─
AlkB Homolog 2, alpha-ketoglutarate-dependent dioxygenase
AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase
D000071499
-
D08.811.682.690.416.139.750
└─
AlkB Homolog 3, alpha-ketoglutarate-dependent dioxygenase
AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase
D000071500
-
D08.811.682.690.416.139.875
└─
AlkB Homolog 4, lysine demethylase
AlkB Homolog 4, Lysine Demethylase
D000071501
-
D08.811.682.690.416.139.937
└─
AlkB Homolog 5, RNA demethylase
AlkB Homolog 5, RNA Demethylase
D000071502
-
D08.811.682.690.416.139.968
└─
Alpha-ketoglutarate-dependent dioxygenase FTO
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
D000071516
-
D08.811.682.690.416.139.992
4 publications dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA.
Department of Chemistry, Stanford University, Stanford, CA, 94305, USA.
Publications dans "AlkB enzymes" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA. raustin@barnard.edu.
Publications dans "AlkB enzymes" :
3 publications dans cette catégorie
Affiliations :
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA.
Publications dans "AlkB enzymes" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA.
Department of Biochemistry and Molecular Biophysics, California Institute of Technology, Pasadena, CA, 91125, USA.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, 94305, USA. liangf@stanford.edu.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), Department of Chemistry , Wuhan University , Wuhan 430072 , P.R. China.
Sauvage Center for Molecular Sciences , Wuhan University , Wuhan 430072 , P.R. China.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), Department of Chemistry , Wuhan University , Wuhan 430072 , P.R. China.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive West, Lethbridge, Alberta T1K 3M4, Canada.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive West, Lethbridge, Alberta T1K 3M4, Canada.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY 10027, USA.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY 10027, USA. Electronic address: raustin@barnard.edu.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
Departamento de Biocatálisis, ICP-CSIC, Campus UAM-CSIC, Madrid, Spain; Center of Excellence in Bionanoscience Research, External Scientific Advisory Academic, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Electronic address: rfl@icp.csic.es.
Publications dans "AlkB enzymes" :
2 publications dans cette catégorie
Affiliations :
R&D Center, BTC Corporation, Ansan 15588, Republic of Korea.
Publications dans "AlkB enzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Publications dans "AlkB enzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Publications dans "AlkB enzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Publications dans "AlkB enzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Barnard College, 3009 Broadway, New York, NY, 10027, USA.
Department of Chemistry, University of Southern California, Los Angeles, CA, 90007, USA.
Publications dans "AlkB enzymes" :
Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of c...
Liver fibrosis is one of the cardinal clinical features of chronic hepatitis C (CHC). However, the mechanisms underlying the evolution and reversion of liver fibrosis after hepatitis C virus (HCV) era...
Between October 2014 and September 2019, 418 patients with CHC or compensated cirrhosis with HCV were prospectively recruited in this observational study. 326 patients that were successfully eradicate...
Ten (3.1%) patients died during the observation period. 4COL7S-defined fibrosis progression (n = 97, 29.8%) at SVR was significantly correlated with worse all-cause mortality post-SVR (P = 0.0062) but...
Peri-treatment dynamics of serum 4COL7S, a non-invasive fibrosis marker, predict prognosis. Non-invasive fibrosis markers may be useful biomarkers for risk stratification post-SVR....
The glomerular basement membrane (GBM) consists of laminins, collagen IV, nidogens, and fibronectin and is essential for filtration barrier integrity in the kidney. Critically, structural and function...
Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is characterized by airflow limitation and an obstructive spirometry pattern without parenchymal opacities. The protein sign...
41 patients who had undergone LTX were enrolled. Of these, 27 developed BOS and 14 (control group) were considered stable at the time of serum sampling. Of BOS patients, serum samples were analysed at...
Serum concentrations of COL4A5 were higher in pre-BOS than in stable patients (40.5 ± 13.9 and 24.8 ± 11.4, respectively, p = 0.048). This protein is not influenced by comorbidities, such as acute rej...
Serum concentrations of COL4A5 can be considered a good prognostic marker due to their association with survival and correlation with functional parameters....
Children with persistent, isolated microscopic hematuria typically undergo a limited diagnostic workup and are monitored for signs of kidney disease in long-term longitudinal follow-up, which can dela...
To determine the clinical utility of genetic screening in this population, we performed targeted genetic testing using a custom, 32-gene next-generation sequencing panel for progressive kidney disease...
In cohort 1 33% of subjects (10/30) had pathogenic or likely pathogenic (P/LP) variants in the type IV collagen genes (COL4A3/A4/A5), and 10% (3/30) had variants of uncertain significance in these gen...
Children with persistent, isolated microscopic hematuria have a high likelihood of having pathogenic variants in type IV collagen genes and genetic screening should be considered. A higher resolution ...
The objective of this study was to develop a serum biochemical marker of the degradation of type III and IV collagens, as an index of synovium turnover, and evaluate its performance in patients with r...
Increased collagen remodelling is a key pathophysiological component underlying intestinal stricture and fistula development in Crohn's disease (CD)....
To investigate associations between serological biomarkers of collagen turnover and disease behaviour according to the Montreal classification in patients with CD....
Serological biomarkers of type III/IV collagen formation (PRO-C3, PRO-C4) and matrix metalloproteinase (MMP) or granzyme-B (GrzB)-mediated type I, III, IV and VI collagen degradation (C1M, C3M, C4M, C...
C1M, C3M and C4M were significantly reduced in patients with stricturing disease (Montreal B2) and accurately differentiated them from patients with either non-stricturing, non-penetrating (B1) or pen...
Elevated degradation of type I, III and IV collagen and excessive (relative) formation of type IV collagen strongly associates with stricturing CD. Type I and IV collagen fragments show predictive pot...
Escherichia coli (E. coli) is one of the main bacteria associated with preterm premature rupture of membranes by increasing pro-matrix metalloproteinase 9 (proMMP-9) and degradation of type IV collage...
Nine HFMi were mounted in a Transwell system. MDec was stimulated with P4 or E. coli for 3-, 6-, or 24-hours. proMMP-2, -9 and type IV collagen were assessed....
Gelatin zymography revealed an increase in proMMP-9 after 3, 6, and 24 h of stimulating MDec with E. coli. Using immunofluorescence, it was confirmed the increase in the HFMi tissue and a reduction on...
P4 modulates the activity of proMMP-9 induced by E. coli stimulation but it was unable to completely reverse the degradation of type IV collagen in human MDec tissue....
X-linked Alport syndrome is a genetic kidney disease caused by pathogenic COL4A5 variants, but little is known of the consequences of missense variants affecting the NC1 domain of the corresponding co...